(Q37685687)

22 August 2017

1 reference

title

Systematic review of the effect of dopamine receptor agonists on patient health-related quality of life (English)

1 reference

22 August 2017

0 references

1 reference

1 reference

1 reference

Pablo Martinez-Martin

series ordinal

1

object named as

Pablo Martinez-Martin

1 reference

22 August 2017

Mónica M Kurtis

2

1 reference

22 August 2017

publication date

1 December 2009

1 reference

Parkinsonism and Related Disorders

22 August 2017

published in

1 reference

22 August 2017

volume

15 Suppl 4

1 reference

22 August 2017

page(s)

S58-64

1 reference

Chemical neuroanatomy of the basal ganglia--normal and in Parkinson's disease

22 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970837-5

7 January 2021

Aromatic Amino Acids and Modification of Parkinsonism

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970837-5

7 January 2021

Treatment of parkinsonism with bromocriptine.

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970837-5

7 January 2021

Practice parameter: initiation of treatment for Parkinson's disease: an evidence-based review: report of the Quality Standards Subcommittee of the American Academy of Neurology

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970837-5

7 January 2021

Drug treatment of Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970837-5

7 January 2021

A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970837-5

7 January 2021

An introduction to the concept of "quality of life in Parkinson's disease".

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970837-5

7 January 2021

Pramipexole vs levodopa as initial treatment for Parkinson disease: a 4-year randomized controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970837-5

7 January 2021

Pramipexole versus levodopa in patients with early Parkinson's disease: effect on generic and disease-specific quality of life

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970837-5

7 January 2021

Effect of medical and surgical interventions on health-related quality of life in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970837-5

7 January 2021

Effect sizes for interpreting changes in health status.

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970837-5

7 January 2021

Identifying meaningful intra-individual change standards for health-related quality of life measures

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970837-5

7 January 2021

Double-blind comparison of pramipexole and bromocriptine treatment with placebo in advanced Parkinson's disease. International Pramipexole-Bromocriptine Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970837-5

7 January 2021

Pramipexole vs levodopa as initial treatment for Parkinson disease: A randomized controlled trial. Parkinson Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970837-5

7 January 2021

Efficacy of cabergoline in long-term use: results of three observational studies in 1,500 patients with Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970837-5

7 January 2021

Randomized trial of tolcapone versus pergolide as add-on to levodopa therapy in Parkinson's disease patients with motor fluctuations

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970837-5

7 January 2021

Pramipexole versus sertraline in the treatment of depression in Parkinson's disease: a national multicenter parallel-group randomized study

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970837-5

7 January 2021

Efficacy and safety of high-dose cabergoline in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970837-5

7 January 2021

Efficacy and tolerability of Entacapone versus Cabergoline in parkinsonian patients suffering from wearing-off

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970837-5

7 January 2021

Use of the dopamine receptor agonist Mirapex in the treatment of Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970837-5

7 January 2021

Ten-year follow-up of Parkinson's disease patients randomized to initial therapy with ropinirole or levodopa

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970837-5

7 January 2021

Transdermal Rotigotine

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970837-5

7 January 2021

Ropinirole 24-hour prolonged release: randomized, controlled study in advanced Parkinson disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970837-5

7 January 2021

Pramipexole in levodopa-treated Parkinson disease patients of African, Asian, and Hispanic heritage

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970837-5

7 January 2021

Efficacy of pramipexole and transdermal rotigotine in advanced Parkinson's disease: a double-blind, double-dummy, randomised controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970837-5

7 January 2021

Conversion from dopamine agonists to cabergoline: an open-label trial in 128 patients with advanced Parkinson disease

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970837-5

7 January 2021

Comparison of apomorphine and levodopa infusions in four patients with Parkinson's disease with symptom fluctuations

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970837-5

7 January 2021

Dopamine agonist monotherapy in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970837-5

7 January 2021

Impact of newer pharmacological treatments on quality of life in patients with Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970837-5

7 January 2021

10.1016/S1353-8020(09)70837-5

Identifiers

DOI

1 reference

22 August 2017

1 reference